Can a faster, Higher-Power heart ablation beat the standard for AFib?

NCT ID NCT07728539

Recruiting now Disease control Sponsor: Bakulev Scientific Center of Cardiovascular Surgery Source: ClinicalTrials.gov ↗

First seen Jul 27, 2026 · Last updated Jul 28, 2026 · Updated 1 time

Summary

This trial tests whether a new high-power short-duration radiofrequency ablation technique (90 watts for 4 seconds) is safer and more effective than the standard low-power approach (35 watts for 10-15 seconds) for treating atrial fibrillation. The study includes adults with paroxysmal or persistent AFib who have not responded to medication. Researchers will track AFib recurrence and complications over 12 months to see which method offers better outcomes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: radiofrequency ablation using high-power short-duration (90 W, 4 s) or standard low-power (35 W, 10-15 s) settings
What this could lead to: If the high-power short-duration approach proves safer and more effective, it could become a new standard for treating atrial fibrillation, reducing recurrence and complications.
What could go wrong: This is a single-center trial with 196 participants, so results may not apply broadly. The high-power technique carries risks like esophageal injury, and it may not outperform the standard method.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE CEREBROVASCULAR ACCIDENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atrial fibrillation Death stroke disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE CEREBROVASCULAR ACCIDENT ATRIAL FIBRILLATION (AF) ATRIAL FIBRILLATION RECURRENT DEATH STROKE

Contacts and locations

Locations

Bakulev National Medical Research Center for Cardiovascular Surgery
RECRUITING

Moscow, 121552, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.